Fifth Lane Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Fifth Lane Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,631	Closed	-$11K	–	220
2022 Q3	$11K	Buy	+14,631	New	+$10K	0.01%	104
2022 Q2	–	Sell	-27,941	Closed	-$25K	–	422
2022 Q1	$25K	Buy	27,941 +3,095	+12%	+$3.45K	0.02%	199
2021 Q4	$56K	Buy	+24,846	New	+$80.4K	0.03%	185

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

JFGLC

Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return

Fifth Lane Capital's DNA.WS Position: Q4 2022 in Review

Fifth Lane Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2022, closing a stake of 14,631 shares — an estimated $11K sold.

Fifth Lane Capital first reported a position in DNA.WS in Q4 2021 and held it in 3 quarters. The position peaked at $56K in Q4 2021. 44 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2022.

Fifth Lane Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2022 after selling out during the quarter.
Fifth Lane Capital sold 14,631 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2022, an estimated $11K.
Fifth Lane Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q4 2021 and held it in 3 quarters.
Fifth Lane Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $56K in Q4 2021.
44 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2022.

Based on Fifth Lane Capital's 13F filing for Q4 2022, filed 14 Feb 2023.